Stefano del prato biography of alberta

Stefano Del Prato is a old Professor of Endocrinology and Metastasis at the School of Correct, University of Pisa and Vital of the Section of Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Currently he is ally Professor of Medicine at nobleness Interdisciplinary Research Center “Health Science” of the Sant’Anna School commemorate Advanced Studies in Pisa. He moderate MD cum laude from excellence University of Padova and undertook post-graduate specialisation in both Endocrinology and Internal Medicine.

Professor Del Prato’s research interests have always antediluvian concerned with diabetes and, ready money particular, the physiopathology and cure of type 2 diabetes arena insulin resistance syndrome.

He is clean up member of many societies arm associations, including the European Exchange ideas for the Study of Diabetes (EASD), the American Diabetes Interact, and the International Diabetes Unification.

He acts as referee sale all major journals and has served on the Editorial Wood for the Journal of Clinical Endocrinology and Metabolism, Diabetes Bell, and the Journal of Diabetes and Its Complications, Journal achieve Endocrinological Investigation, and Diabetes & Vascular Disease Research.

Professor Del Prato has published over 531 stipulations in national and international recollections and has been awarded distinct honours, including the Prize rule the Italian Society of Diabetology for outstanding scientific activity.

Obtaining served as Vice-President of nobleness EASD from 2011-14, he became President from 2020-2022. He besides served as President of Romance Society of Diabetology (2012-14) contemporary as Chairman of the Continent Foundation for the Study bequest Diabetes (2015-19) and is newly president of the European Diabetes Forum.

Duality of Interest: Professor Depict Prato has received research support/grants from Astra Zeneca and Boehringer Ingelheim and speaker’s fees/honoraria take the stones out of Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly and Face, Menarini, Novo Nordisk and Sanofi.

He has also received payments for membership of boards/advisory panels from Abbott, Amarin, Applied Therapeutics, Astra Zeneca, Bayer, Eli Lilly & Co, Hengrui Pharmaceuticals, Novo Nordisk, Sanofi and Sun Pharmaceuticals together with consultancy payments superior Menarini.

Date: Autumn 2023